# Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis

> **NCT05511766** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Tanta University** · enrollment: 150 (estimated)

## Conditions studied

- Cirrhosis
- Hepatic Encephalopathy
- Ascites
- Varices
- SBP - Spontaneous Bacterial Peritonitis

## Interventions

- **DRUG:** Allopurinol 300 MG
- **DRUG:** Atorvastatin 20mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05511766
- **Lead sponsor:** Tanta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-15
- **Primary completion:** 2024-04-25
- **Final completion:** 2025-01-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05511766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05511766, "Allopurinol Versus Atorvastatin to Prevent Complications of Liver Cirrhosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05511766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*